Business Context and Reporting Period
Company: Acadia Healthcare Company, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 18, 2024
Event: Entry into a Material Definitive Agreement (Amendment No. 2 to Credit Agreement).
Key Financial Metrics and Debt Structure
This filing details a modification to the company's debt facilities rather than reporting operational financial performance metrics such as revenue or profit.
- Revolving Credit Facility: $600 million senior secured (unchanged).
- Existing Term Loan Facility: $425 million senior secured (unchanged).
- Incremental Term Loans: New borrowing of $350 million senior secured term loans.
- Total Term Loan Capacity Post-Amendment: $775 million ($425 million existing + $350 million incremental).
- Maturity Date: March 17, 2026 (for both Revolving and Term Loan facilities).
- Interest Rate: Floating rate equal to adjusted SOFR plus 1.50% or alternative base rate plus 0.500%, subject to adjustment based on the consolidated total net leverage ratio.
- Collateral: Secured by a pledge of substantially all assets of the Company and Guarantors (excluding real property and certain customarily excluded assets).
Material Changes Versus Prior Period
The primary material change is the incurrence of $350 million in additional senior secured term loans (Incremental Term Loans). These loans are structured as an increase to the Existing Term Loan Facility. The terms regarding maturity, leverage-based pricing, amortization, and mandatory prepayment events for the new loans are substantially identical to the pre-amendment terms.
Use of Proceeds, Risks, and Management Commentary
Use of Proceeds: The proceeds from the $350 million Incremental Term Loans are designated for working capital and other general corporate purposes. Specifically, the filing notes these funds may be used for the payment of litigation settlements and transaction costs.
Risks and Contingencies: The filing highlights that the obligations are guaranteed by substantially all direct or indirect wholly-owned U.S. subsidiaries. The interest rate is variable and tied to the company's consolidated total net leverage ratio, introducing interest rate risk dependent on future leverage performance.
Management Commentary: The filing does not contain qualitative management commentary regarding operational outlook or strategic shifts beyond the execution of the debt amendment.
Investor Verification Checklist
- Verify the specific amount of litigation settlements to be paid with the new proceeds, as this impacts future cash flow requirements.
- Review the company's current consolidated total net leverage ratio to determine the applicable interest rate margin under the pricing grid.
- Examine the full text of Amendment No. 2 to Credit Agreement (Exhibit 10.1) for any covenants or restrictions not summarized in the 8-K.
- Confirm the status of the $600 million Revolving Facility to assess remaining liquidity headroom.